Europe In Vitro Diagnostics Market Outlook to 2017

  • Posted by Rahul Thakur
  • Monday, January 16, 2012

GlobalData’s new report, “Europe In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the Europe In Vitro Diagnostics market – France, Germany, Italy, Spain and United Kingdom. The report provides value (USD million) data for all the market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

Europe In Vitro Diagnostics Market Outlook to 2017

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

  • Countries covered include France, Germany, Italy, Spain and United Kingdom.
  • Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
  • Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2003 to 2010, forecast forward for 7 years to 2017.
  • 2010 company shares and distribution shares data for each of the market categories and countries.
  • Global corporate-level profiles of key companies operating within the Europe In Vitro Diagnostics market.
  • Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., bioMerieux S.A., Ortho-Clinical Diagnostics Inc. and others.

Reasons to buy

  • Develop business strategies by identifying the key market categories and segments poised for strong growth.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the Europe In Vitro Diagnostics competitive landscape.
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 12

2 Introduction 14
2.1 What is This Report About? 14

3 In Vitro Diagnostics in Europe 15
3.1 In Vitro Diagnostics Cross Country Comparison, USD Actual, 2003-2017 15
3.2 In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, 2003-2017 16
3.3 In Vitro Diagnostics, Europe, Company share (2009-2010) 24

4 In Vitro Diagnostics In Germany 26
4.1 In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, 2003-2017 26
4.2 In Vitro Diagnostics, Germany, Distribution Share (2009-2010) 32
4.3 In Vitro Diagnostics, Germany, Company share (2009-2010) 36

5 In Vitro Diagnostics In France 52
5.1 In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, 2003-2017 52
5.2 In Vitro Diagnostics, France, Distribution Share (2009-2010) 58
5.3 In Vitro Diagnostics, France, Company share (2009-2010) 62

6 In Vitro Diagnostics In Italy 78
6.1 In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, 2003-2017 78
6.2 In Vitro Diagnostics, Italy, Distribution Share (2009-2010) 84
6.3 In Vitro Diagnostics, Italy, Company share (2009-2010) 88

7 In Vitro Diagnostics In United Kingdom 104
7.1 In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 104
7.2 In Vitro Diagnostics, United Kingdom, Distribution Share (2009-2010) 110
7.3 In Vitro Diagnostics, United Kingdom, Company share (2009-2010) 114

8 In Vitro Diagnostics In Spain 130
8.1 In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, 2003-2017 130
8.2 In Vitro Diagnostics, Spain, Distribution Share (2009-2010) 136
8.3 In Vitro Diagnostics, Spain, Company Share (2009-2010) 140

9 Overview of Key Companies in Europe In Vitro Diagnostics Market 156
9.1 F. Hoffmann-La Roche Ltd. 156
9.2 Siemens Healthcare 157
9.3 Abbott Laboratories 158
9.4 Beckman Coulter, Inc. 159
9.5 bioMerieux S.A. 160
9.6 Ortho-Clinical Diagnostics Inc. 161
9.7 Sysmex Corporation 162
9.8 Bio-Rad Laboratories, Inc. 162
9.9 Becton, Dickinson and Company 162
9.10 DiaSorin S.p.A 163
9.11 Phadia AB 163
9.12 Alere Inc. 163
9.13 DIAGNOSTICA STAGO, Inc. 164
9.14 Qiagen N.V. 164
9.15 Gen-Probe Incorporated 164
9.16 HORIBA, Ltd. 165
9.17 Thermo Fisher Scientific Inc. 165
9.18 Grifols, S.A. 165
9.19 PerkinElmer, Inc. 166
9.20 Danaher Corporation 166
9.21 The Elitech Group 166
9.22 BioSystems International 167
9.23 Life Technologies Corporation 167
9.24 Immucor, Inc. 167
9.25 Hologic, Inc. 168
9.26 Cellestis Limited 168
9.27 Atlas Medical 168

10 In Vitro Diagnostics Market Pipeline Products 169
10.1 Clinical Chemisty Market Pipeline Products 169
10.2 Immuno Chemistry Market Pipeline Products 172
10.3 Haematology Market Pipeline Products 175
10.4 Infectious Immunology Market Pipeline Products 177
10.5 Microbiology Culture Market Pipeline Products 181
10.6 Histology and Cytology Market Pipeline Products 182
10.7 Genetic Testing Market Pipeline Products 183

11 Financial Deals Landscape 188
11.1 Merger 188
11.2 Acquisition 189
11.3 Partnerships 220

12 Recent Developments 291
12.1 Strategy And Business Planning 291
12.2 Legal and Regulatory 308
12.3 Government and Public Interest 313
12.4 Product News 329

13 Appendix 364
13.1 Definitions of Markets Covered in the Report 365
13.2 Research Methodology 367
13.3 Secondary Research 367
13.4 Primary Research 368
13.5 Models 368
13.6 Forecasts 369
13.7 Expert Panels 369
13.8 GlobalData Consulting 369
13.9 Currency Conversion 370
13.10 Contact Us 370
13.11 Disclaimer 370

List of Tables

Table 1:In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017 25
Table 2:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, 2003-2017 27
Table 3:In Vitro Diagnostics, Europe, Cross-Category Analysis, 2003-2017 29
Table 4:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Historic, 2003-2010 31
Table 5:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 33
Table 6:In Vitro Diagnostics, Europe, Company Share by Revenue ($m), USD Actual, 2009-2010 35
Table 7:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, 2003-2017 37
Table 8:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Historic, 2003-2010 39
Table 9:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 41
Table 10:Clinical Chemistry, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 42
Table 11:Genetic Testing, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 42
Table 12:Haematology, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 43
Table 13:Histology And Cytology, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 43
Table 14:Immuno Chemistry, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 44
Table 15:Infectious Immunology, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 44
Table 16:Microbiology Culture, Germany, Distribution Share by Revenue ($m), USD Actual, 2009-2010 45
Table 17:In Vitro Diagnostics, Germany, Company share by Revenue ($m), USD Actual, 2009-2010 47
Table 18:Clinical Chemistry, Germany, Company share by Revenue ($m), USD Actual 2009-2010 49
Table 19:Genetic Testing, Germany, Company share by Revenue ($m), USD Actual 2009-2010 51
Table 20:Haematology, Germany, Company share by Revenue ($m), USD Actual 2009-2010 53
Table 21:Histology And Cytology, Germany, Company share by Revenue ($m), USD Actual 2009-2010 55
Table 22:Immuno Chemistry, Germany, Company share by Revenue ($m), USD Actual 2009-2010 57
Table 23:Infectious Immunology, Germany, Company share by Revenue ($m), USD Actual 2009-2010 59
Table 24:Microbiology Culture, Germany, Company share by Revenue ($m), USD Actual 2009-2010 61
Table 25:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, 2003-2017 63
Table 26:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Historic, 2003-2010 65
Table 27:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 67
Table 28:Clinical Chemistry, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 68
Table 29:Genetic Testing, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 68
Table 30:Haematology, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 69
Table 31:Histology And Cytology, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 69
Table 32:Immuno Chemistry, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 70
Table 33:Infectious Immunology, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 70
Table 34:Microbiology Culture, France, Distribution Share by Revenue ($m), USD Actual, 2009-2010 71
Table 35:In Vitro Diagnostics, France, Company share by Revenue ($m), USD Actual, 2009-2010 73
Table 36:Clinical Chemistry, France, Company share by Revenue ($m), USD Actual 2009-2010 75
Table 37:Genetic Testing, France, Company share by Revenue ($m), USD Actual 2009-2010 77
Table 38:Haematology, France, Company share by Revenue ($m), USD Actual 2009-2010 79
Table 39:Histology And Cytology, France, Company share by Revenue ($m), USD Actual 2009-2010 81
Table 40:Immuno Chemistry, France, Company share by Revenue ($m), USD Actual 2009-2010 83
Table 41:Infectious Immunology, France, Company share by Revenue ($m), USD Actual 2009-2010 85
Table 42:Microbiology Culture, France, Company share by Revenue ($m), USD Actual 2009-2010 87
Table 43:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, 2003-2017 89
Table 44:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Historic, 2003-2010 91
Table 45:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 93
Table 46:Clinical Chemistry, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 94
Table 47:Genetic Testing, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 94
Table 48:Haematology, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 95
Table 49:Histology And Cytology, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 95
Table 50:Immuno Chemistry, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 96
Table 51:Infectious Immunology, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 96
Table 52:Microbiology Culture, Italy, Distribution Share by Revenue ($m), USD Actual, 2009-2010 97
Table 53:In Vitro Diagnostics, Italy, Company share by Revenue ($m), USD Actual, 2009-2010 99
Table 54:Clinical Chemistry, Italy, Company share by Revenue ($m), USD Actual 2009-2010 101
Table 55:Genetic Testing, Italy, Company share by Revenue ($m), USD Actual 2009-2010 103
Table 56:Haematology, Italy, Company share by Revenue ($m), USD Actual 2009-2010 105
Table 57:Histology And Cytology, Italy, Company share by Revenue ($m), USD Actual 2009-2010 107
Table 58:Immuno Chemistry, Italy, Company share by Revenue ($m), USD Actual 2009-2010 109
Table 59:Infectious Immunology, Italy, Company share by Revenue ($m), USD Actual 2009-2010 111
Table 60:Microbiology Culture, Italy, Company share by Revenue ($m), USD Actual 2009-2010 113
Table 61:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 115
Table 62:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Historic, 2003-2010 117
Table 63:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 119
Table 64:Clinical Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 120
Table 65:Genetic Testing, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 120
Table 66:Haematology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 121
Table 67:Histology And Cytology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 121
Table 68:Immuno Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 122
Table 69:Infectious Immunology, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 122
Table 70:Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USD Actual, 2009-2010 123
Table 71:In Vitro Diagnostics, United Kingdom, Company share by Revenue ($m), USD Actual, 2009-2010 125
Table 72:Clinical Chemistry, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 127
Table 73:Genetic Testing, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 129
Table 74:Haematology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 131
Table 75:Histology And Cytology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 133
Table 76:Immuno Chemistry, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 135
Table 77:Infectious Immunology, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 137
Table 78:Microbiology Culture, United Kingdom, Company share by Revenue ($m), USD Actual 2009-2010 139
Table 79:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, 2003-2017 141
Table 80:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Historic, 2003-2010 143
Table 81:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 145
Table 82:Clinical Chemistry, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 146
Table 83:Genetic Testing, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 146
Table 84:Haematology, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 147
Table 85:Histology and Cytology, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 147
Table 86:Immuno Chemistry, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 148
Table 87:Infectious Immunology, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 148
Table 88:Microbiology Culture, Spain, Distribution Share by Revenue ($m), USD Actual, 2009-2010 149
Table 89:In Vitro Diagnostics, Spain, Company Share by Revenue ($m), USD Actual, 2009-2010 151
Table 90:Clinical Chemistry, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 153
Table 91:Genetic Testing, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 155
Table 92:Haematology, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 157
Table 93:Histology and Cytology, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 159
Table 94:Immuno Chemistry, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 161
Table 95:Infectious Immunology, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 163
Table 96:Microbiology Culture, Spain, Company Share by Revenue ($m), USD Actual 2009-2010 165
Table 97: Clinical Chemisty Market Pipeline Products 179
Table 98: Immuno Chemistry Market Pipeline Products 182
Table 99: Haematology Market Pipeline Products 185
Table 100: Infectious Immunology Market Pipeline Products 187
Table 101: Microbiology Culture Market Pipeline Products 191
Table 102: Histology and Cytology Market Pipeline Products 192
Table 103: Genetic Testing Market Pipeline Products 193
Table 104:Centre For Molecular Medicine And Human Genetics Unit Merge To Form IGMM 198
Table 105:Roche To Acquire Verum Diagnostica For $17.4 Million 199
Table 106:Lepu Medical Technology To Acquire 40% Stake In Comed For $1.9 Million 200
Table 107:Alere Receives Valid Acceptance For Revised Offer To Acquire Axis-Shield For $385 Million 201
Table 108:Grifols Acquires Remaining 51% Stake In Lateral-Medion 203
Table 109:PZ Cormay Acquires 98.62% Stake In Audit Diagnostics 204
Table 110:Roche Completes Acquisition Of mtm laboratories 205
Table 111:bioMerieux Acquires Argene 207
Table 112:Qiagen To Acquire 61% Stake In IPSOGEN 208
Table 113:Lab21 Acquires Myconostica 210
Table 114:Thermo Fisher Completes Acquisition Of Phadia 211
Table 115:bioMerieux Completes Acquisition Of AES Laboratoire 213
Table 116:Ion Beam Applications Acquires 25% Stake In PET Net 215
Table 117:Qiagen Completes Acquisition Of Cellestis 216
Table 118:Techne Acquires Boston Biochem And Boston Biochem 218
Table 119:Merck Acquires heipha Dr. Muller And Related Assets From Biotest 219
Table 120:Agilent Technologies Acquires Lab901 221
Table 121:PerkinElmer Acquires Chemagen Biopolymer 223
Table 122:Imperial Innovations Acquires Minority Stake In Molecular Vision 225
Table 123:AlphaHelix Molecular Diagnostics Acquires Techtum Lab 226
Table 124:ERBA DIAGNOSTICS MANNHEIM Acquires Diasis Diagnostic Systems 227
Table 125:Addtech Life To Acquire Electra-Box Diagnostica 228
Table 126:Lab21 Acquires Microgen Bioproducts 229
Table 127:Global BioDiagnostics Extends Co-Development Agreement With Foundation for Innovative New Diagnostics 230
Table 128:Sony DADC Enters Into Co-Development Agreement With Axela 231
Table 129:Roche Enters Into Joint Venture Agreement With Swiss Federal Institute of Technology, University of Zurich And University Hospital Zurich 232
Table 130:Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies 234
Table 131:Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals 235
Table 132:Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics 236
Table 133:SuperNova Diagnostics Enters Into Co-Development Agreement With Concile 237
Table 134:Dako Enters Into Co-Development Agreement With Bristol-Myers 238
Table 135:Transgenomic Enters Into Distribution Agreement With ScreenCell 239
Table 136:Oxford Gene Technology Enters Into Co-Development Agreement With Abcodia 240
Table 137:Horizon Discovery Enters Into Co-Development Agreement With Promega 241
Table 138:Sony DADC Enters Into Co-Development Agreement With Anagnostics Bioanalysis 242
Table 139:Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 243
Table 140:Axis-Shield Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics 244
Table 141:TcLand Expression Enters Into Co-Development Agreement With Radboud University Nijmegen 245
Table 142:Generation Scotland Enters Into Co-Development Agreement With Arrayjet 246
Table 143:Accelr8 Technology Amends Licensing Agreement With SCHOTT 247
Table 144:Orion Genomics Enters Into Licensing Agreement With QIAGEN 248
Table 145:Almac Group Enters Into Research Agreement With Queen’s University Belfast 249
Table 146:QIAGEN Enters Into Co-Development Agreement With Eli Lilly 250
Table 147:Skyline Diagnostics Enters Into Research Agreement With Clavis Pharma 251
Table 148:Lumora Enters Into Licensing Agreement With 3M 252
Table 149:Quanterix Enters Into Co-Development Agreement With STRATEC Biomedical 253
Table 150:Sequenom Enters Into Licensing Agreement With LifeCodexx 254
Table 151:Enigma Diagnostics Enters Into Co-Development Agreement With GlaxoSmithKline 255
Table 152:BD Diagnostics Enters Into Co-Development Agreement With Lab21 256
Table 153:Hycor Biomedical Signs Licensing Agreement With Eurospital 257
Table 154:Hycor Biomedical Signs Licensing Agreement With Axis-Shield 258
Table 155:Quanterix Enters Into Co-Development Agreement With Sony DADC 259
Table 156:Mayo Medical Laboratories Enters Into Licensing Agreement With Qiagen 260
Table 157:Proteome Sciences Enters Into Collaboration With Buck Institute 261
Table 158:Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center 262
Table 159:Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharmaceutical 263
Table 160:Metamark Genetics Enters Into Co-Development Agreement With Definiens 264
Table 161:Bruker Daltonics Enters Into Distribution Agreement With Francisco Soria Melguizo 265
Table 162:Roche Enters Into Collaboration With Evotec 266
Table 163:Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 267
Table 164:ResearchDx Enters Into Partnership With CompanDX 268
Table 165:Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina 269
Table 166:University of Geneva, Hopitaux Universitaires de Geneve, SIB And Roche Form Partnership 270
Table 167:F. Hoffmann-La Roche Enters Into Co-Development Agreement With Merck 271
Table 168:Roche Enters Into Co-Development Agreement With Clovis Oncology 272
Table 169:Roche Applied Science Enters Into Partnership With TIB MOLBIOL 273
Table 170:Pacific Edge Biotechnology Enters Into Licensing Agreement With Oryzon Genomics 274
Table 171:EKF Diagnostics Enters Into Distribution Agreement With Alere 275
Table 172:AbD Serotec Enters Into Licensing Agreement With Proteomika 276
Table 173:BD Diagnostic Enters Into Co-Development Agreement With Diagenode 277
Table 174:Atonomics Enters Into An Agreement With Beckman Coulter 278
Table 175:Royal Philips Electronics Enters Into Co-Development Agreement With NEC 279
Table 176:Precision System Science Enters Into Co-Development Agreement With Biotrin International 280
Table 177:Genmab Enters Into Research Collaboration With Seattle Genetics 281
Table 178:Biofortuna Enters Into Distribution Agreement With Abbott 282
Table 179:Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 283
Table 180:DNA Genotek Enters Into Distribution Agreement With Abyntek Biopharma 284
Table 181:BioFocus Enters Into An Agreement With Almac Group 285
Table 182:Seegene Enters Into An Agreement With Molzym 286
Table 183:Dako Denmark Enters Into Co-Development Agreement With Epitomics 287
Table 184:Accelrys Enters Into Co-Development Agreement With Oxford Nanopore 288
Table 185:Ascent Scientific Enters Into Licensing Agreement With Children’s Memorial Hospital And The University Of Newcastle 289
Table 186:Genomic Expression Enters Into An Agreement With Copenhagen University, Beijing Genome Institute And Bavarian Nordic 290
Table 187:BioPorto Enters Into Licensing Agreement With Instrumentation Laboratory 291
Table 188:Oxford Medical Diagnostics Enters Into Co-Marketing Agreement With V&F Analyse 292
Table 189:FIND Enters Into An Agreement With Global BioDiagnostics 293
Table 190:Epigenomics Enters Into Research Licensing Agreement With QIAGEN 294
Table 191:CompanDX Enters Into Agreement With Clinical Reference Laboratory 295
Table 192:Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 296
Table 193:PROGEN Biotechnik Enters Into Distribution Agreement With Mitsubishi Chemical 297
Table 194:NorDiag Enters Into Agreement With Precision System Science 298
Table 195:Consort Medical Enters Into Co-Development Agreement With Atlas Genetics 299
Table 196:Cepheid Enters Into Co-Development Agreement With FIND 300
Table 197: USD to Local Currency, Europe, Average Exchange Rate 2003-2010 380

List of Figures

Figure 1:In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017 25
Figure 2:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, 2003-2017 26
Figure 3:In Vitro Diagnostics, Europe, Cross-Category Analysis, 2003-2017 28
Figure 4:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Historic, 2003-2010 30
Figure 5:In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 32
Figure 6:In Vitro Diagnostics, Europe, Company share (%), 2010 34
Figure 7:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, 2003-2017 36
Figure 8:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Historic, 2003-2010 38
Figure 9:In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 40
Figure 10:In Vitro Diagnostics, Germany, Company Share (%), 2010 46
Figure 11:Clinical Chemistry, Germany, Company Share (%), 2010 48
Figure 12:Genetic Testing, Germany, Company Share (%), 2010 50
Figure 13:Haematology, Germany, Company Share (%), 2010 52
Figure 14:Histology And Cytology, Germany, Company Share (%), 2010 54
Figure 15:Immuno Chemistry, Germany, Company Share (%), 2010 56
Figure 16:Infectious Immunology, Germany, Company Share (%), 2010 58
Figure 17:Microbiology Culture, Germany, Company Share (%), 2010 60
Figure 18:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, 2003-2017 62
Figure 19:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Historic, 2003-2010 64
Figure 20:In Vitro Diagnostics, France, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 66
Figure 21:In Vitro Diagnostics, France, Company Share (%), 2010 72
Figure 22:Clinical Chemistry, France, Company share (%), 2010 74
Figure 23:Genetic Testing, France, Company share (%), 2010 76
Figure 24:Haematology, France, Company share (%), 2010 78
Figure 25:Histology And Cytology, France, Company share (%), 2010 80
Figure 26:Immuno Chemistry, France, Company share (%), 2010 82
Figure 27:Infectious Immunology, France, Company share (%), 2010 84
Figure 28:Microbiology Culture, France, Company share (%), 2010 86
Figure 29:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, 2003-2017 88
Figure 30:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Historic, 2003-2010 90
Figure 31:In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 92
Figure 32:In Vitro Diagnostics, Italy, Company share (%), 2010 98
Figure 33:Clinical Chemistry, Italy, Company share (%), 2010 100
Figure 34:Genetic Testing, Italy, Company share (%), 2010 102
Figure 35:Haematology, Italy, Company share (%), 2010 104
Figure 36:Histology And Cytology, Italy, Company share (%), 2010 106
Figure 37:Immuno Chemistry, Italy, Company Share (%), 2010 108
Figure 38:Infectious Immunology, Italy, Company share (%), 2010 110
Figure 39:Microbiology Culture, Italy, Company share (%), 2010 112
Figure 40:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, 2003-2017 114
Figure 41:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Historic, 2003-2010 116
Figure 42:In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 118
Figure 43:In Vitro Diagnostics, United Kingdom, Company share (%), 2010 124
Figure 44:Clinical Chemistry, United Kingdom, Company share (%), 2010 126
Figure 45:Genetic Testing, United Kingdom, Company share (%), 2010 128
Figure 46:Haematology, United Kingdom, Company share (%), 2010 130
Figure 47:Histology And Cytology, United Kingdom, Company share (%), 2010 132
Figure 48:Immuno Chemistry, United Kingdom, Company share (%), 2010 134
Figure 49:Infectious Immunology, United Kingdom, Company share (%), 2010 136
Figure 50:Microbiology Culture, United Kingdom, Company share (%), 2010 138
Figure 51:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, 2003-2017 140
Figure 52:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Historic, 2003-2010 142
Figure 53:In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 144
Figure 54:In Vitro Diagnostics, Spain, Company Share (%), 2010 150
Figure 55:Clinical Chemistry, Spain, Company Share (%), 2010 152
Figure 56:Genetic Testing, Spain, Company Share (%), 2010 154
Figure 57:Haematology, Spain, Company Share (%), 2010 156
Figure 58:Histology and Cytology, Spain, Company Share (%), 2010 158
Figure 59:Immuno Chemistry, Spain, Company Share (%), 2010 160
Figure 60:Infectious Immunology, Spain, Company Share (%), 2010 162
Figure 61:Microbiology Culture, Spain, Company Share (%), 2010 164
Figure 62:F. Hoffmann-La Roche Ltd., Company Share (%), Europe In Vitro Diagnostics Market, 2010 166
Figure 63:Siemens Healthcare, Company Share (%), Europe In Vitro Diagnostics Market, 2010 167
Figure 64:Abbott Laboratories, Company Share (%), Europe In Vitro Diagnostics Market, 2010 168
Figure 65:Beckman Coulter, Inc., Company Share (%), Europe In Vitro Diagnostics Market, 2010 169
Figure 66:bioMerieux S.A., Company Share (%), Europe In Vitro Diagnostics Market, 2010 170
Figure 67:Ortho-Clinical Diagnostics Inc., Company Share (%), Europe In Vitro Diagnostics Market, 2010 171

Global Siding Market is forecast to grow 4.8 percent per year through 2015

  • Posted by Rahul Thakur
  • Friday, December 16, 2011

World demand to rise 4.8% annually through 2015
The global siding market is forecast to grow 4.8 percent per year through 2015 to over five billion square meters, with demand in residential and nonresidential applications growing at similar paces. Heightened residential demand will be measured against a low 2010 base in many industrialized countries, which are expected to rebound somewhat from the losses of the 2005-2010 period. Residential demand for siding will remain strong in developing countries as personal income levels rise and construction practices improve, increasing the number of buildings using siding. Nonresidential demand for siding will grow most rapidly in the developing
Asia/Pacific and Africa/Mideast regions, where real GDP is expected to rise at rates above the global average, fueling building construction spending.

Global Siding Market

North America, Asia/Pacific regions to post strong gains
North America is projected to be by far the most rapidly growing regional siding market during the 2010-2015 period. Demand will rise the fastest in the United States as the US housing sector recovers somewhat from its collapse in the previous period, but US siding sales in 2015 will remain well below the level reached in 2005. Led by China and India, and assisted by recoveries in the Japanese, South Korean, and Australian markets, the Asia/Pacific region is expected
to post strong gains. Growth in the other developing regions will be spurred by ongoing industrial and commercial development and rising personal income levels, which will make siding roducts more affordable for residential construction. In Eastern Europe, growth will be restrained by a declining population and decreasing demand for new housing. Sales in Western Europe will also not return to the levels achieved in 2005. Masonry and concrete products will account for nearly three-quarters of sales through 2015. Global demand for these products is expected to grow lmost five percent per year, fueled by recoveries in the housing sectors of the United States and Western Europe. Brick and tile products will enjoy above-average sales growth in China, India and the Africa/Mideast region. Between 2010 and 2015, demand for fiber cement siding will grow most rapidly, taking market share from competitive products. Japan will continue to be the leading national market for fiber cement siding, but gains will also be boosted by strong growth in China and India. Sales of vinyl siding are expected to increase rapidly because of higher levels of US demand, but vinyl siding will remain a niche product outside North America, accounting for only a small portion of demand.

Study coverage
Details on these and other findings are presented in the new Freedonia industry study, World Siding (Cladding), priced at $6100. It presents historical demand data for the years 2000, 2005 and 2010, as well as forecasts for 2015 and 2020 by cement type, market, world region and for 20 countries. In addition, the study considers key market environment factors, assesses global industry structure, evaluates company market share data and profiles 42 industry players worldwide.

This study can help you:
Determine your market & sales potential
Learn more about industry competitors
Assess new products & technologies
Identify firms to merge with or acquire
Complement your research & planning
Gather data for presentations
Confirm your own internal data
Make better business decisions
COM PANY PRO FILES
Profiles 42 global industry players such as HeidelbergCement, JS Group, James Hardie, Nichiha, Saint-Gobain and Wienerberger

Additional Information
This study analyzes the global market for exterior siding or cladding for residential and nonresidential buildings. The following types of products are covered: masonry and concrete (i.e., stone, brick, tile, stucco, exterior insulation and finish systems (EIFS), nonloadbearing concrete and fiber cement); metal (including aluminum and steel siding and metal panels); vinyl; wood (plywood, hardboard, other engineered wood and wood shingles) and other siding. Primary loadbearing walls (of brick, concrete block, poured concrete, stone, etc.) are excluded from the scope of this study, as is glass curtain wall. Secondary products such as soffits and trim are excluded as well.

Historical data for 2000, 2005 and 2010 and forecasts to 2015 and 2020 are provided for siding demand by product type and by market on a country-bycountry basis, measured in million square meters. The term “demand” actually refers to “apparent consumption” and is defined as production (also referred to as “output” or “supply”) from a nation’s indigenous siding manufacturing facilities plus imports minus exports. It is used interchangeably with the terms “market,” “sales” and “consumption.”
In addition, major global siding manufacturers are identified and profiled, and the key competitive variables are discussed. The entire report is framed within the world siding industry’s economic, technological and market environments, and therefore environmental variables affecting siding demand (especially building construction expenditures) are emphasized. World siding market share data by company presented in the “Industry Structure” section are estimated based on consultation with multiple sources. In addition, tabular details may not always add to totals due to rounding.

Data on global siding demand are derived from differing sources and developed from statistical relationships. As a result, variations are commonplace in this type of international reporting, and, consequently, data presented in this study are historically consistent but may differ from othersources. Variances may occur because of definitional differences, undistributed exports, inventory accumulation and goods-in-transit.

Economic and demographic indicators presented in this study were obtained from The Freedonia Group Consensus Forecasts dated August 2011. Gross Domestic Product (GDP) historical data are derived from the national income and products accounts from the Organisation for Economic Co-Operation and Development (OECD) for its member countries, from the European Bank for Reconstruction and Development (EBRD) for its member countries, and from the International Monetary Fund for its member countries that are not part of the OECD or EBRD. GDP estimates for other nations are based on information from the World Bank and a variety of other sources, including the countries’ statistical bureaus. GDP forecasts are developed from a consensus of public agencies and private firms.

All estimates of gross domestic product and components of GDP are done in terms of constant purchasing power parity in a benchmark year (2009) that is one year before the base year (2010) used in this study. Purchasing power parity GDP estimates for the benchmark year are obtained from the OECD, Eurostat, the World Bank, the International Monetary Fund, the US Central Intelligence Agency and selected other sources. These purchasing power parity GDP estimates for the benchmark year are based on gross domestic product data expressed in the individual countries’ local currency, which are then converted to US dollars by valuing each country’s output at US prices in the benchmark year.

This approach values the same physical output at a consistent price for all countries, thereby reducing the distorting influence of different price levels in the different countries. The alternative approach of using exchange rates to convert local currency GDP to US dollars would tend to overvalue the output of countries with high average price levels and undervalue the output of countries with low average price levels, because exchange rate conversions only partially
reflect the relative prices for goods and services that are domestically consumed and invested. Furthermore, factors other than relative prices, such as demand and supply in currency markets, interest rates and capital flows, affect exchange rates.

Once the GDP values for a country are estimated for the benchmark year, we then calculate inflation-adjusted GDP for all other years for that country based on historical and forecast growth rates of GDP expressed in inflationadjusted units of that country’s local currency. This approach ensures that the GDP series for any given country is an accurate index of changes in inflationadjusted GDP for that country. However, it also implicitly assumes that the price structures across countries do not change from those of the benchmark year. Therefore, caution should be used in comparing the relative GDP of countries in years other than the benchmark year. If the ratio of prices across two countries in a given year differs from the ratio of prices across those countries in the benchmark year, then the change in the relative sizes of those two economies as measured will not accurately reflect changes in output.

The benchmark year is chosen to be one year prior to the base year for the study for reasons of data availability. One benefit of this choice is that the ratio of prices across countries in the base year is usually similar to that in the benchmark year. Therefore, the ratio of real GDP between two countries in the base year of 2010 is generally a reasonably accurate representation of the relative sizes of their economies.
A wide variety of primary and secondary sources were used in the compilation of this report. These include government statistical agencies, trade associations such as the Metal Cladding and Roofing Manufacturers Association of the UK and Vinyl Siding Institute of the US, industry experts, financial sources, and siding company sources. Public sector data sources used include the US Bureau of the Census, United Nations, OECD, World Bank, IMF, European Union and various national government statistical publications. Primary information was gathered through consultations with officers and marketing personnel of participating companies. Secondary data and background information were obtained from various trade publications,including Concrete Homes, Concrete Products, ENR, Home Energy Magazine, Masonry, Metal Construction News, Professional Builder, Stone World and Walls & Ceilings. Corporate annual reports, SEC Form 10-K filings, product literature and other company information were also used in framing the industry and market environments and as input for market size assessments.

Table Of Contents
INTRODUCTION x
1. EXECUTIVE SUMMARY 1
2. MARKET ENVIRONMENT 4General 4World Economic Outlook 5Recent Historical Trends 5World Economic Outlook 7World Demographic Overview 10Population 11Households 12Personal Income Trends 14World Building Construction Outlook 16Relationship to Siding Demand 19Residential 22Nonresidential 23Pricing Patterns 25Technology Trends 28Legal & Regulatory Environment 30
3. SUPPLY & DEMAND 33General 33Demand by Region 34Demand by Product 39Masonry & Concrete 41Brick & Tile 44Stucco & EIFS 46Concrete & Stone 49Fiber Cement 51Metal 54Vinyl 57Wood & Other 59Wood 61Other 62Demand by Market 63Residential Buildings 65New Construction 66Improvement & Repair 67Nonresidential Buildings 67New Construction 68Improvement & Repair 69Production & Foreign Trade 70
4. NORTH AMERICA 72General 72Siding Demand 74United States 78Canada 83Mexico 87
5. WESTERN EUROPE 92General 92Siding Demand 94Germany 97France 101United Kingdom 105Spain 109Italy 113Netherlands 118Other Western Europe 122
6. ASIA/PACIFIC 126General 126Siding Demand 128China 132Japan 137India 142South Korea 147Australia 151Indonesia 156Other Asia/Pacific 159
7. OTHER REGIONS 167Central & South America 167Brazil 173Other Central & South America 177Eastern Europe 184Russia 189Poland 194Other Eastern Europe 197Africa/Mideast 205Turkey 210Iran 213Other Africa/Mideast 217
8. INDUSTRY STRUCTURE 225General 225Industry Composition 227Market Share 230Product Development & Manufacturing 233Marketing & Distribution 236Cooperative Agreements 238Mergers & Acquisitions 240Company Profiles 242Acme Brick, see Berkshire HathawayAlcoa Incorporated 243Allied Building Products, see CRHAlside, see Associated MaterialsAsahi Tostem Exterior Building Materials, see JS GroupASC Profiles, see BlueScope SteelAssociated Materials LLC 246BASF SE 249Bayer IMSA, see VerzatecBerkshire Hathaway Incorporated 251BlueScope Steel Limited 253Boral Limited 260Butler Manufacturing, see BlueScope SteelCertainTeed, see Saint-GobainCrane Plastics Siding, see Georgia GulfCRH plc 264CSR Limited 268Dryvit Systems, see RPM InternationalEternit, see Etex GroupEtex Group SA 271Exterior Portfolio by Crane, see Georgia GulfFeatherlite Building Products, see Berkshire HathawayGarco Building Systems, see NCI Building SystemsGeneral Shale Brick, see Wienerberger BaustoffindustrieGentek Building Products, see Associated MaterialsGeorgia Gulf Corporation 275Georgia-Pacific, see Koch IndustriesGlen-Gery, see CRHGrillo-Werke AG 278Hanson, see HeidelbergCementHardie (James) Industries SE 280HCI Steel Building Systems, see BlueScope SteelHeidelbergCement AG 284Heidelberger Kalksandstein, see HeidelbergCementIbstock Brick, see CRHJS Group Corporation 288Kaycan Limited 290Kingspan Group plc 292Knauf Gips KG 294Koch Industries Incorporated 295KP Building Products, see KaycanLIXIL, see JS GroupLouisiana-Pacific Corporation 297Marazzi Group SpA 299Mastic Home Exteriors, see Ply Gem HoldingsMateris Holding Luxembourg SA 300Metal Building Components, see NCI Building SystemsMetalcorp Steel, see BlueScope SteelMetl-Span, see BlueScope SteelMitsubishi Chemical Holdings Corporation 303Napco, see Ply Gem HoldingsNCI Building Systems Incorporated 304Nichiha Corporation 307Oldcastle Architectural, see CRHOOO Kraspan 309Owens Corning Masonry Products, see BoralParex Group, see Materis Holding LuxembourgPermasteelisa SpA 311Ply Gem Holdings Incorporated 313PT BlueScope Steel Indonesia, see BlueScope SteelResolite, see VerzatecRHEINZINK, see Grillo-WerkeRoyal Group, see Georgia GulfRPM International Incorporated 316Saint-Gobain 319Steelscape, see BlueScope SteelSto AG 323Tata BlueScope Steel, see BlueScope Steel and Tata SteelTata Steel Limited 325U-kon International GmbH 327Varco Pruden Buildings, see BlueScope SteelVariform, see Ply Gem HoldingsVerzatec SA de CV 328Weyerhaeuser Company 329Wienerberger Baustoffindustrie AG 331Additional Companies in the Siding Industry 334List Of Tables
SECTION I — EXECUTIVE SUMMARYSummary Table 3SECTION II — MARKET ENVIRONMENT1 World Gross Domestic Product by Region 102 World Population by Region 123 World Households by Region 144 World Per Capita GDP by Region 165 World Building Construction Expenditures by Region 186 World Residential Building Construction Expendituresby Region 237 World Nonresidential Building Construction Expendituresby Region 258 World Siding Pricing 27SECTION III — SUPPLY & DEMAND1 World Siding Demand by Region 382 World Siding Demand by Product 403 World Masonry & Concrete Siding Demand by Product& Region 434 World Brick & Tile Siding Demand by Region 465 World Stucco & EIFS Siding Demand by Region 486 World Concrete & Stone Siding Demand by Region 517 World Fiber Cement Siding Demand by Region 548 World Metal Siding Demand by Region 579 World Vinyl Siding Demand by Region 5910 World Wood & Other Siding Demand by Product & Region 6011 World Siding Demand by Market 64SECTION IV — NORTH AMERICA1 North America — Market Environment for Siding 732 North America — Siding Demand 773 United States — Market Environment for Siding 804 United States — Siding Demand 835 Canada — Market Environment for Siding 856 Canada — Siding Demand 877 Mexico — Market Environment for Siding 898 Mexico — Siding Demand 91SECTION V — WESTERN EUROPE1 Western Europe — Market Environment for Siding 932 Western Europe — Siding Demand 963 Germany — Market Environment for Siding 984 Germany — Siding Demand 1005 France — Market Environment for Siding 1026 France — Siding Demand 1047 United Kingdom — Market Environment for Siding 1068 United Kingdom — Siding Demand 1089 Spain — Market Environment for Siding 11010 Spain — Siding Demand 11311 Italy — Market Environment for Siding 11512 Italy — Siding Demand 11713 Netherlands — Market Environment for Siding 11914 Netherlands — Siding Demand 12115 Other Western Europe — Market Environment for Siding 12316 Other Western Europe — Siding Demand 125SECTION VI — ASIA/PACIFIC1 Asia/Pacific — Market Environment for Siding 1282 Asia/Pacific — Siding Demand 1313 China — Market Environment for Siding 1344 China — Siding Demand 1375 Japan — Market Environment for Siding 1396 Japan — Siding Demand 1427 India — Market Environment for Siding 1448 India — Siding Demand 1469 South Korea — Market Environment for Siding 14810 South Korea — Siding Demand 15111 Australia — Market Environment for Siding 15312 Australia — Siding Demand 15513 Indonesia — Market Environment for Siding 15714 Indonesia — Siding Demand 15915 Other Asia/Pacific — Market Environment for Siding 16116 Other Asia/Pacific — Siding Demand 163SECTION VII — OTHER REGIONS1 Central & South America — Market Environment for Siding 1692 Central & South America — Siding Demand 1723 Brazil — Market Environment for Siding 1744 Brazil — Siding Demand 1765 Other Central & South America — Market Environmentfor Siding 1786 Other Central & South America — Siding Demand 1817 Eastern Europe — Market Environment for Siding 1858 Eastern Europe — Siding Demand 1889 Russia — Market Environment for Siding 19110 Russia — Siding Demand 19311 Poland — Market Environment for Siding 19512 Poland — Siding Demand 19713 Other Eastern Europe — Market Environment for Siding 19914 Other Eastern Europe — Siding Demand 20215 Africa/Mideast — Market Environment for Siding 20716 Africa/Mideast — Siding Demand 20917 Turkey — Market Environment for Siding 21118 Turkey — Siding Demand 21319 Iran — Market Environment for Siding 21520 Iran — Siding Demand 21721 Other Africa/Mideast — Market Environment for Siding 21922 Other Africa/Mideast — Siding Demand 221SECTION VIII — INDUSTRY STRUCTURE1 Siding Sales for Selected Manufacturers, 2010 2292 Selected Cooperative Agreements 2393 Selected Acquisitions & Divestitures 241

List Of Charts
SECTION II — MARKET ENVIRONMENT1 World Building Construction Expenditures by Region, 2010 192 Relationship Between Per Capita Siding Demand & Per CapitaBuilding Construction Expenditures, 2010 213 World Siding Pricing, 2000-2020 28SECTION III — SUPPLY & DEMAND1 World Siding Demand by Region, 2010 392 World Siding Demand by Type, 2010 413 World Siding Demand by Market, 2000-2020 64SECTION VIII — INDUSTRY STRUCTURE1 World Siding Market Share by Company, 2010 230

US Stretch & Shrink Film Market demand to reach $2.4 billion in 2015

  • Posted by Rahul Thakur

US demand for stretch and shrink film will rise 3.3 percent per year to $2.4 billion in 2015, driven by accelerating demand for product packaging and for the bundling and protection of goods during warehousing and distribution, as well as by competitive advantages over other packaging materials. Other stimulants will include resin and machinery improvements, and opportunities in areas such as stretch hoods and stretch labels and sleeves.

Stretch & Shrink Film Market

LDPE is leading stretch and shrink film resin
Stretch film demand will increase 2.8 percent annually through 2015, benefiting from advantages in energy and labor savings. The fastest growth is anticipated for stretch hoods due to their cost advantages, high throughput rates and excellent load integrity and weather protection. Demand for shrink film will grow 4.2 percent annually to $970 million in 2015. Advances will be promoted by shrink film’s high clarity and excellent print capabilities, greatly enhancing product marketability. In particular, growth will be aided by increased use in labels. Shrink film also provides a seal and moisture barrier and is frequently used in conjunction with corrugated trays as a case overwrap. Demand for stretch and shrink film resins is expected to rise 2.5 percent annually to 1.9 billion pounds in 2015. Low density polyethylene (LDPE) is the leading stretch and shrink film resin due to its competitive cost and excellent elongation, puncture-resistance and other properties. Demand for LDPE stretch and shrink film is forecast to see healthy growth through 2015. LDPE resins consist of linear low density polyethylene (LLDPE) as well as conventional LDPE. LLDPE’s high impact strength, elongation properties and downgauging potential; and conventional LDPE’s greater clarity and drawdown characteristics lead to their dominant usage. Polyvinyl chloride (PVC) stretch and shrink film demand will remain relatively flat through 2015 in volume terms, though gains will be seen in value terms. Shrink sleeve labels for foods and beverages will be the primary area of opportunity for PVC, with other areas declining as a result of PVC’s poor environmental image and competition from LDPE films.Other smaller stretch and shrink film resins include polypropylene, high density polyethylene, polyester (e.g., polyethylene terephthalate) and biodegradable resins.

Storage & distribution market to post above average gains
The storage and distribution market for stretch and shrink film will post aboveaverage increases through 2015, when these uses will account for over half of total demand. Advances will be stimulated by growing retail trade and industrial activity, as well as export markets. The primary growth driver will be pallet wrap, due to its competitive advantages over strapping, tape and other bulk unitization methods. Product packaging demand gains will be stimulated by growing retail trade and concomitant needs for product packaging for food, beverage, consumer and other items. Stretch and shrink film advantages include cost effectiveness and source reduction capabilities compared to corrugated boxes and other packaging.

Study coverage
This new Freedonia industry study, Stretch & Shrink Film, is available for $4800. It presents historical demand data (2000, 2005 and 2010) plus forecasts for 2015 and 2020 by type, market and resin. The study also considers market environment factors, assesses industry structure,evaluates company market share and profiles 33 competitors in the US industry.
This study can help you:
Determine your market & sales potential
Learn more about industry competitors
Assess new products & technologies
Identify firms to merge with or acquire
Complement your research & planning
Gather data for presentations
Confirm your own internal data
Make better business decisions
COMPANY PROFILES
Profiles 33 US industry players including AEP Industries, Bemis, Berry Plastics and Sigma Plastics
Additional Information
This study examines the stretch and shrink film industry in the US by type, resin, product, application and market. Historical data are provided for 2000, 2005 and 2010, with forecasts for 2015 and 2020. “Demand” is equal to US production plus imports minus exports. This is synonymous with terms such as “sales” and “apparent consumption.” Value data reflects demand at the manufacturers’ level. In addition, the key strategic and competitive variables affecting the US paper and plastic packaging industries are discussed, and market leaders are identified and profiled. The entire study is framed within the context of overall economic conditions, as well as demographic, regulatory and technological factors affecting stretch and shrink film and their users.

Throughout this study, demand is related to various indicators for comparative purposes and to facilitate further analysis. Tabular details may not add to totals due to independent rounding, and calculated ratios reflect unrounded numbers. Corporate information sources included annual reports, SEC Form 10-K filings, analyst reports, product catalogs and other company information. The macroeconomic indicators used in this study were obtained from The Freedonia Group Consensus Forecasts dated August 2011. Due to the Bureau of Economic Analysis’ use of chain-weighted price indices, inflationadjusted GDP components (2005 dollars) may not add to the total.

Information and data on the stretch and shrink film industry were obtained from a variety of primary and secondary sources. Consultations with film producers, resin producers, resin distributors, end users, consultants, industry specialists and trade association personnel were pursued. Secondary data were obtained from government, trade associations and other private sources, including the Plastics Division of the American Chemistry Council. Other sources included trade publications such as Chemical Week; ICIS Chemical Business; International Association of Plastics Distributors; Modern Plastics; Paper, Film & Foil Converter; Plastics Engineering; Plastics News; and Plastics Technology. Corporate information sources included annual reports, SEC Form10-K filings, product releases, prospectuses and conversations with responsible officers within the companies themselves.

Government and trade association publications, security analyst reports and numerous other publications were utilized, and online databases were also searched. Throughout this study, demand is related to various indicators for comparative purposes and to facilitate further analysis. Tabular details may not add to totals due to independent rounding, and calculated ratios reflect unrounded numbers.

Table Of Contents
INTRODUCTION ix
1. EXECUTIVE SUMMARY 1
2. MARKET ENVIRONMENT 4General 4Macroeconomic Outlook 5Demographic Trends 8Consumer Income & Spending 12Retail Sales Outlook 15Manufacturing Outlook 17Nondurable Goods Outlook 19Food & Beverage Industry Overview 21Fresh Produce Outlook 24Packaging Industry Overview 26Plastic Film Industry Overview 29Technological Developments 33Pricing Trends 35Regulatory & Environmental Considerations 38Recycling 39Foreign Trade 40International Activity 41
3. TYPES 42General 42Stretch Film 43Production Methods 44Resins 46Products 49Wrap 50Stretch Labels & Sleeves 52Hoods 53Applications 55Markets 57Storage & Distribution 58Product Packaging 62Producers 66Shrink Film 68Resins 69Products 74Wrap 76Labels 77Bags 79Hoods & Other 80Applications 81Markets 83Product Packaging 84Storage & Distribution 88Producers 89
4. MARKETS 92General 92Product Packaging 93Food 95Meat, Poultry & Seafood 97Dairy 101Fresh Produce 102Other Foods 103Beverages 104Paper & Textile Products 105Paper 107Textiles 108Consumer Products 108Types 110Uses 111Other Product Packaging 111Agriculture 112All Other 113Storage & Distribution 113Pallet Wrap 114Stretch 115Shrink 116Other Storage & Distribution 117
5. RESINS 119General 119Low Density Polyethylene 121Linear Low Density Polyethylene 123Conventional LDPE 124Producers 124Polyvinyl Chloride 125Other Resins 128
6. INDUSTRY STRUCTURE 133General 133Market Share 134Mergers & Acquisitions 136Marketing Strategies 140Channels & Distribution 141Research & Development 142Competitive Strategies 144Manufacturing & Development 145Cooperative Agreements 146Company Profiles 148AEP Industries Incorporated 149Alcan Packaging Food Americas, see BemisAlliance Plastics LLC 151Allied Plastics, see Sigma PlasticsAmerican Fuji Seal, see Fuji Seal InternationalAmTopp, see InteplastApplied Extrusion Technologies Incorporated 152Bemis Company Incorporated 153Berry Plastics Corporation 157Bollore 160Bonset America, see ITOCHUCenveo Incorporated 162CMS Gilbreth Packaging Systems, see CenveoCoastal Films of Florida, see Sigma PlasticsCryovac, see Sealed AirCurwood, see BemisDow Chemical Company 164DuPont (EI) de Nemours 166Dwyer (RB) Company Incorporated 167Exopack Holding Corporation 168Exxon Mobil Corporation 170FlexSol Packaging, see Sigma PlasticsFuji Seal International Incorporated 172Hood Companies Incorporated 173Ideal Sleeves International, see Dwyer (RB)Illinois Tool Works Incorporated 174Impaxx, see CenveoInteplast Group Limited 176Intertape Polymer Group Incorporated 178ISO Poly Films, see Sigma PlasticsITOCHU Corporation 180ITW-GaleWrap, see Illinois Tool WorksKlöckner Pentaplast Group 182LINPAC Group Limited 183LyondellBasell Industries NV 184McNeely Plastic Products, see Sigma PlasticsMercury Plastics, see Sigma PlasticsMRI Flexible Packaging 186Multi-Color Corporation 187Paragon Films Incorporated 188Performance Packaging, see Sigma PlasticsPinnacle Films, see InteplastPliant, see Berry PlasticsPoly-America LP 189Poly Plastic Products, see Sigma PlasticsPoly Plastic Products of North Carolina,see Sigma PlasticsPresto Products, see Reynolds GroupPrintpack Incorporated 191Reynolds Group Holdings Limited 192Santa Fe Packaging, see Sigma PlasticsSealed Air Corporation 195Sigma Plastics Group 197Signode Packaging Systems, see Illinois Tool WorksSKC Company Limited 200SleeveCo 201Strapex, see Illinois Tool WorksUp North Plastics, see Poly-AmericaVIBAC Group SpA 203Vifan USA, see VIBACWestern Plastics Limited 204

List Of Tables
SECTION I — EXECUTIVE SUMMARYSummary Table 3SECTION II — MARKET ENVIRONMENT1 Macroeconomic Indicators 82 Population & Households 123 Personal Consumption Expenditures 144 Retail Sales 175 Manufacturers’ Shipments 196 Nondurable Goods Shipments 217 Food & Beverage Shipments 248 Fresh Produce Production 269 Packaging Supply & Demand 2810 Plastic Film Demand by Resin 3211 Stretch & Shrink Film Pricing 38SECTION III — TYPES1 Stretch & Shrink Film Demand by Type 432 Stretch Film Demand by Production Method 453 Stretch Film Demand by Resin 484 Stretch Film Demand by Product 505 Stretch Film Demand by Application 566 Stretch Film Demand by Market 587 Stretch Film Demand in Storage & Distribution by Use 598 Stretch Film Demand in Product Packaging by Use 639 Shrink Film Demand by Resin 7310 Shrink Film Demand by Product 7511 Shrink Film Demand by Application 8212 Shrink Film Demand by Market 8413 Shrink Film Demand in Product Packaging by Use 8714 Shrink Film Demand in Storage & Distribution by Use 89SECTION IV — MARKETS1 Stretch & Shrink Film Demand by Type & Market 932 Product Packaging Market for Stretch & Shrink Film 943 Food Markets for Stretch & Shrink Film by Type & Use 964 Meat, Poultry & Seafood Markets for Stretch & Shrink Filmby Type 985 Dairy Markets for Stretch & Shrink Film by Type 1026 Fresh Produce Markets for Stretch & Shrink Film by Type 1037 Other Food Markets for Stretch & Shrink Film by Type 1048 Beverage Markets for Shrink Film 1059 Paper & Textile Markets for Stretch & Shrink Filmby Type & Use 10710 Consumer Markets for Stretch & Shrink Film by Type & Use 10911 Other Stretch & Shrink Film Demand by Type & Use 11212 Storage & Distribution Markets for Stretch & Shrink Film 114SECTION V — RESINS1 Stretch & Shrink Film Demand by Resin 1202 Low Density Polyethylene Demand in Stretch & Shrink Filmby Type & Resin 1223 Polyvinyl Chloride Demand in Stretch & Shrink Film by Type 1274 Other Resins Demand in Stretch & Shrink Filmby Resin & Type 132SECTION VI — INDUSTRY STRUCTURE1 Selected Acquisitions & Divestitures 1392 Selected Cooperative Agreements 147

List Of Charts
SECTION II — MARKET ENVIRONMENT1 Plastic Film Demand by Resin, 2010 33SECTION III — TYPES1 Stretch Film Demand by Resin, 2010 492 Stretch Film Demand by Application, 2010 573 Stretch Film Demand in Product Packaging by Use, 2010 644 Shrink Film Demand by Resin, 2010 735 Shrink Film Demand by Product, 2010 756 Shrink Film Demand by Application, 2010 837 Shrink Film Demand in Product Packaging by Use, 2010 88SECTION IV — MARKETS1 Product Packaging Market for Stretch & Shrink Film, 2010 952 Food Markets for Stretch & Shrink Film by Use, 2010 973 Consumer Markets for Stretch & Shrink Film by Use, 2010 110SECTION V — RESINS1 Stretch & Shrink Film Demand by Resin, 2010 1212 PVC Demand in Stretch & Shrink Film by Type, 2010 128SECTION VI — INDUSTRY STRUCTURE1 US Stretch & Shrink Film Market Share, 2010 134

Laboratory Information Systems (LIS / LIMS) Markets

  • Posted by Rahul Thakur
  • Wednesday, January 5, 2011

Original Source: http://www.webmarketingindia.org/article/laboratory-information-systems-lis-lims-markets/

Automating instruments in the laboratory has created a demand for similar automation of information management systems, a need for speeding the turnaround of data and increased access to information resources. For this reason, the market for computer systems in the lab is a need-to-know area both for IT companies and diagnostic companies.

Laboratory Information Systems (LIS / LIMS) Markets

Laboratory information systems (LIS), also known as laboratory information management systems (LIMS), are data and information management systems designed specifically for industrial and medical-related laboratories. This report provides market analysis of suppliers competing in the LIMS market. The report also provides an overview of the industry and detail on important trends in the market including: middleware trends, the Abbott acquisition of Starlims, on-demand LIMS, user interface trends, managing genomics, among others.

Segmented Market Size Estimates and Forecasts

This Kalorama Information report, Laboratory Information Systems (LIS/LIMS Markets), focuses on the market for LIS for clinical health care labs and pharmaceutical drug discovery laboratories, although other aspects of drug research and development labs are mentioned. The report includes market size and forecast data for the following segments:

  • Clincial LIS, North America
  • Clinical LIS, World
  • Clinical LIS Software
  • Clinical LIS Hardware
  • Drug Discovery LIS, North America
  • Drug Discovery LIS, World

Profiles of Over 50 LIS Companies

As with most Kalorama reports, this report was the result of primary research into the LIS market. In addition to market statistics, this report provides coverage of vendor offerings, trends in choosing LIS / LIMS systems, vendor concerns, trends in M&A in the industry, as well as detailed company profiles. This report discusses the following companies:

  • AAC Infotray AG
  • Abbott Starlims Corp.
  • Accelerated Technology Laboratories Inc.
  • AJ Blomesystem GmbH
  • Antek HealthWare
  • ASM Soft SL
  • Baytek International
  • Benetech Medical Systems
  • Blaze Systems
  • Caliber Infosolutions Inc.
  • CambridgeSoft
  • ChemWare Inc.
  • Clinical Software Solutions
  • Clinical Systems Ltd.
  • Common Cents Systems
  • Core Informatics *
  • Custom Software Ltd.
  • Data Unlimited International Inc.
  • Desarrollo Aplicaciones Sanitarias SL
  • eBioSys Pty Ltd.
  • Eclipsys Corp.
  • Elekta AB 115
  • F. Hoffmann-La Roche Ltd.
  • GenoLogics Life Sciences Software Inc.
  • GraphLogic Inc.
  • H&A Scientific Inc.
  • Ingensis Ltd.
  • Interface Engineering Co. Ltd.
  • ISYS/Biovation
  • Kriti Microsystems Pvt. Ltd.
  • LabLogic Systems Ltd.
  • LabVantage Solutions Inc.
  • LabWare Inc.
  • LIMS at work GmbH
  • McKesson Provider Technologies
  • Modul-Bio
  • Multidata Computer Systems Inc.
  • NeTLIMS NJ, LLC
  • NXG Group
  • Odysis SA
  • Orchard Software Corp.
  • Polisystem Informatica Srl
  • Sapio Sciences LLC
  • SCC Soft Computer
  • Sciformatix
  • Software Point Oy
  • Technidata
  • Thermo Fisher Scientific
  • Timeless Medical Systems
  • Two Fold Software Ltd.
  • VelQuest
  • Visual Access Health Systems Pvt. Ltd.
  • Zumatrix Inc.

Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. The market data are generated into multiple year forecasts for different product segments covered in the report. The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives and researchers.

Laboratory Information Systems (LIS / LIMS) Markets

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

1.1 Overview
1.1.1 Insights
1.1.2 Variety of Functions 4
1.1.3 Emerging Trends 5
1.2 The Case for Automation
1.2.1 Integration
1.3 Key Challenges and Issues
1.3.1 Competition, Regulations, Changing Business Requirements 9
1.4 World Market Summary
1.5 Methodology

CHAPTER TWO: INTRODUCTION

2.1 Origination and History
2.1.1 Building on Basic Platforms
2.1.2 LIMS versus LIS
2.2 Key Niches and Capabilities
2.2.1 Automation
2.2.2 Interconnectivity
2.2.3 Integration
2.2.3.1 Meeting Organizational Objectives
2.3 Creating More Efficient Labs
2.3.1 Effective Data Management
2.3.2 Better Sample Management
2.4 Trends 32
2.4.1 Commercial Off the Shelf Systems
2.4.1.1 For the Pharma Lab
2.4.4.2 For the Clinical Lab
2.4.2 Web-Based Systems
2.4.3 Cost Reduction
2.5 Key Issues
2.5.1 Enterprise Management
2.5.2 Point of Care Testing
2.5.3 Choosing a System
2.5.4 Vendor Concerns

CHAPTER THREE: RECENT MARKET DEVELOPMENTS

3.1 Transforming LIS
3.2 Enhancing LIS
3.3 Next Generation Pathology System
3.4 Middleware Trends
3.5 LIS Optimizing Quality
3.6 Abbott Acquires Starlims
3.7 Licensing
3.8 On-Demand LIMS
3.9 User Interface
3.10 Tool Kit
3.11 Information Sharing
3.12 Forum
3.13 Managing Genomics
3.14 Understanding the Needs of the End User
3.15 Automating the Laboratory

CHAPTER FOUR: MARKETS

4.1 Overview
4.2 Reshaping Markets for LIS
4.2.1 Niche Markets
4.2.1.1 The Clinical Laboratory
4.2.1.2 The Drug Discovery Laboratory
4.3 High Performance, User Friendly Systems
4.4 Benefits for the Market
4.5 Merger and Acquisition Activity
4.6 Market Perspective
4.6.1 Clinical Laboratory LIS
4.6.1.1 Market Analysis and Forecasts
4.6.2 Drug Discovery LIS

CHAPTER FIVE: CORPORATE PROFILES

5.1 AAC Infotray AG
5.2 Abbott Starlims Corp.
5.3 Accelerated Technology Laboratories Inc.
5.4 AJ Blomesystem GmbH
5.5 Antek HealthWare
5.6 ASM Soft SL
5.7 Baytek International
5.8 Benetech Medical Systems
5.9 Blaze Systems
5.10 Caliber Infosolutions Inc.
5.11 CambridgeSoft
5.12 ChemWare Inc.
5.13 Clinical Software Solutions
5.14 Clinical Systems Ltd.
5.15 Common Cents Systems
5.16 Core Informatics
5.17 Custom Software Ltd.
5.18 Data Unlimited International Inc.
5.19 Desarrollo Aplicaciones Sanitarias SL
5.20 eBioSys Pty Ltd.
5.21 Eclipsys Corp.
5.22 Elekta AB 115
5.23 F. Hoffmann-La Roche Ltd.
5.24 GenoLogics Life Sciences Software Inc.
5.25 GraphLogic Inc.
5.26 H&A Scientific Inc.
5.27 Ingensis Ltd.
5.28 Interface Engineering Co. Ltd.
5.29 ISYS/Biovation
5.30 Kriti Microsystems Pvt. Ltd.
5.31 LabLogic Systems Ltd.
5.32 LabVantage Solutions Inc.
5.33 LabWare Inc.
5.34 LIMS at work GmbH
5.35 McKesson Provider Technologies
5.36 Modul-Bio
5.37 Multidata Computer Systems Inc.
5.38 NeTLIMS NJ, LLC
5.39 NXG Group
5.40 Odysis SA
5.41 Orchard Software Corp.
5.42 Polisystem Informatica Srl
5.43 Sapio Sciences LLC
5.44 SCC Soft Computer
5.45 Sciformatix
5.46 Software Point Oy
5.47 Technidata
5.48 Thermo Fisher Scientific
5.49 Timeless Medical Systems
5.50 Two Fold Software Ltd.
5.51 VelQuest
5.52 Visual Access Health Systems Pvt. Ltd.
5.53 Zumatrix Inc.

LIST OF EXHIBITS

Exhibit 1: World Market for Clinical Laboratory Information Systems 2010-2015
Exhibit 2: World Market for Drug Discovery Laboratory Information Systems 2010-2015
Exhibit 3: LIS Development Timetable
Exhibit 4: Key LIS Selection Issues
Exhibit 5: World Market for Clinical LIS 2010-2015
Exhibit 6: World Market for Clinical LIS 2010-2015
Exhibit 7: North American Market for Clinical LIS 2010-2015 b
Exhibit 8: North American Market for Clinical LIS 2010-2015
Exhibit 9: World Market for Clinical LIS, Software and Hardware 2010-2015
Exhibit 10: World Market for Clinical LIS, Software and Hardware 2010-2015
Exhibit 11: North American Market for Clinical LIS, Software and Hardware 2010-2015
Exhibit 12: North American Market for Clinical LIS, Software and Hardware 2010-2015
Exhibit 13: World Market for Drug Discovery LIS 2010-2015
Exhibit 14: World Market for Drug Discovery LIS 2010-2015
Exhibit 15: North American Market for Drug Discovery LIS 2010-2015
Exhibit 16: North American Market for Drug Discovery LIS 2010-2015
Exhibit 17: World Market for Drug Discovery LIS, Software and Hardware 2010-2015
Exhibit 18: World Market for Drug Discovery LIS, Software and Hardware 2010-2015
Exhibit 19: North American Market for Drug Discovery LIS, Software and Hardware 2010-2015
Exhibit 20: North American Market for Drug Discovery LIS, Software and Hardware 2010-2015

Laboratory Information Systems (LIS / LIMS) Markets

ARRA Energy Report Card: Two Years Later

  • Posted by Rahul Thakur

Original Source: http://www.webmarketingindia.org/article/arra-energy-report-card-two-years-later/

Introduction At $94.8 billion, clean energy investments account for the largest portion, 30 percent, of ARRA appropriations directed for innovative infrastructure improvements. This public spending in the form of direct funds and tax incentives were appropriated to encourage innovation and adoption of clean energy technologies, establishing a foundation for a national transition to a clean energy economy. ARRA energy-related funding not only presents potential near-term economic benefits, but also long-term economic and strategic investment and a transformative opportunity for the energy sector.

ARRA Energy Report Card: Two Years Later

The greatest opportunities to reduce energy consumption and carbon emissions can be found in the transportation, power, and residential and commercial buildings sectors. To this end, ARRA clean energy provisions represent an array of investments in advances in clean transportation, renewable power generation, modernization of the electric transmission and distribution grid, carbon capture and sequestration, and building efficiency. These investments support the development, production, and/or deployment of a host of both new and existing technologies, industry training to install, operate, and maintain these technologies, and community outreach programs to facilitate market conditioning to accelerate adoption of new, energy efficient products and methods.

The Transportation Sector received the greatest stimulus boost in terms of sheer dollar allotment with more than $22 billion to promote the development, production, and purchase of energy efficient transportation solutions and technologies. ARRA funding of mass transit will be essential to reversing the years of infrastructure deterioration, the declining service reliability for transit riders, the increasing maintenance costs for transit operators, and the worrisome limitations on the ability to expand system capacity at a time of high demand. Meanwhile, ARRA investment in advanced vehicles and fuels has the potential to someday deliver affordable electric cars that can drive 300 miles on a single charge, powered by $10 of clean electricity instead of $50 of oil—a scenario that could emancipate the country from its reliance on imported oil.

The Power Sector received the second highest allotment of ARRA funding with almost $21 billion, lead by investments in the smart grid that approached $11 billion. Smart grid investment, can be regarded as the biggest stimulus winner in terms of latent impact because the favorable implementation of various other ARRA energy initiatives—increasing renewable electricity generation and enabling electric vehicles while simultaneously ensuring reliability of electric service—hinges on successful grid modernization. In addition, maximizing the efficiency of the smart grid is widely viewed as the incident that will usher in an era of energy independence for the U.S. ARRA has demonstrated substantial effects within the Power Sector. For example, growth in renewable energy has increased since 2009, despite recessionary conditions, due in large part to ARRA. This will enable the U.S. to make significant progress toward meeting a goal of doubling its renewable generation capacity by 2012. Without ARRA investments, it is likely that the pace of renewable energy project construction and manufacturing growth would have otherwise slowed dramatically due the sharp economic and financial downturn over this period.

Lastly, the more than $18 billion dedicated to the Building Sector will aid the anticipated—and substantial—increase in building renovation aimed at making structures more energy efficient to combat rising energy costs and adverse environmental impacts. Energy efficiency gains in residential and commercial buildings as a direct result of ARRA are expected to decrease overall energy consumption of these sectors by nearly 3% in 2015. The EIA estimates that the savings in energy expenditures from these efficiency gains will exceed $13 billion in 2020.

Finally, one key success factor for the ARRA has been its ability to leverage federal funding with co-investments from the private sector and state and local governments to complement its investments in a wide range of activities. ARRA direct investments and tax incentives of about $95 billion in clean energy programs requiring co-investments will support about $250 billion in total investments in clean energy markets.

ARRA Energy Report Card: Two Years Later

Report Scope

  • ARRA Energy Report Card: Two Years Later examines the ARRA clean energy investments and their impact on the various clean energy markets within the power, transportation, and building sectors. The report presents the ARRA direct investments, segmented by sector and clean energy market, and provides details with regard to cross-sector energy-related ARRA investments and tax incentives. A summary of the clean energy markets within each sector likely to be impacted by ARRA energy investments is presented, along with obligations to date, and potential impact and estimated market size to 2015. Several examples of specific projects are also included.
  • ARRA direct investments made in the power, transportation, and buildings sectors are discussed in detail. The report includes specific program details, appropriations amounts, awardees, and intent. Further, the markets expected to benefit from ARRA provisions are highlighted by sector. Discussion of these markets includes products and technologies and estimated market size to 2015.
  • Identification and profiling of twenty private-sector companies that have received American Recovery and Reinvestment Act awards under clean energy programs discussed in the report. These companies represent some of the largest total ARRA clean energy awards made to private sector companies to date. Recipient awards in the categories of renewable generation, grid modernization, carbon capture and sequestration, transportation, and energy efficiency are represented. Key profile information, brief descriptions of company activities, and discussion of company ARRA clean energy award activities are provided.

Report Methodology

The information in ARRA Energy Report Card: Two Years Later is based on primary and secondary research. Primary research entailed interviews with firms involved in the manufacture, distribution and sales of various clean energy technologies, systems and products, analysts and consultants to the energy industry to obtain insight into the products, technologies and market factors shaping the industry. Secondary research entailed data gathering from relevant sources, including government resources including: National Renewable Energy Laboratory (NREL), United States Department of Energy (DOE), United States Energy Information Administration (EIA); international institutions including the International Energy Agency (IEA), industry resources, company literature, SEC filings, and corporate annual reports.

What You’ll Get in This Report

ARRA Energy Report Card: Two Years Later contains important insights and projections regarding the future of clean energy markets impacted by ARRA investments and pinpoints ways current and prospective players can benefit from ARRA funding and related growth in these markets. No other market research report provides both the comprehensive analysis and extensive data that ARRA Energy Report Card: Two Years Later offers. Subscribers will benefit from extensive data, presented in easy-to-read and practical charts, tables, and graphs.

How You’ll Benefit from This Report

If your company is already doing business related to clean energy solutions, or is engaged in activities pertaining to renewable energy generation, smart grid, clean coal/carbon sequestration, energy storage, electric vehicles, components, and infrastructure, biofuels, mass transit, or building energy efficiency, you will find this report invaluable. It provides a comprehensive package of information and insight not offered in any other single source. You will gain a thorough understanding of the ARRA investments and impact on clean energy markets, as well as the projected market size and trends for the clean energy markets mentioned above.

This report will help:

  • Marketing managers understand the forces shaping the market for commercial available clean energy technologies and identify market opportunities.
  • Research and development professionals stay on top of competitor initiatives and explore demand for clean energy technologies.
  • Business development executives understand the dynamics of the various clean energy markets discussed and identify possible partnerships.
  • Information and research center librarians provide market researchers, product managers, and other colleagues with the vital information they need to do their jobs more effectively.

Additional Information

Market Insights: A Selection From The Report

ARRA Residential and Commercial Buildings Energy Efficiency Investments

Many of the provisions of ARRA target energy efficiency associated with residential and commercial buildings. Federal funding is provided to assist states and local governments in implementing energy efficiency programs, weatherize public housing, improve energy efficiency and renewable energy use in federal and military buildings, encourage purchase of energy efficient appliances, and to support small business research, development, and deployment of clean energy technologies. In addition to such direct investment, ARRA includes provisions that expand and revise tax credits for energy-efficient products purchased and installed in residential and commercial buildings. SBI Energy has identified nearly $18 billion across 12 direct investment programs funded through ARRA to promote the purchase and development of energy efficient products and technologies.

Table 1-4
ARRA Clean Energy Programs, Residential and Commercial Buildings
(in $ B)

Market for Solar Power

Solar power can be generally defined as radiation from the sun transformed into an energy source. Since the sun radiates both light and heat, two corresponding technologies have been developed to harness each form: solar electric or photovoltaic (PV) technology converts the sun’s light into electricity; solar thermal (ST) technology converts the sun’s heat into energy.

Technologies

The basic unit of all solar electric technology is the photovoltaic (PV) cell. PV cells generate electricity by exploiting the “photovoltaic effect” where, under certain conditions, electrons flow through semiconductor materials when exposed to sunlight. At the heart of the PV cell is the semiconductor base. Currently, silicon, in amorphous, mono-crystalline or polycrystalline form, is the preferred material used for this purpose because…

Market for Advanced Fuels

Biomass is organic matter that can be converted into liquid fuels or electricity. Primary biomass feedstocks are harvested or collected from the fields or forests where they are grown. Examples of primary biomass feedstocks include grains and oilseed crops used for transportation fuel production, and some residues from logging and forest operations that are…

High Speed Rail (HSR) Technologies

SBI Energy analyzed the business plans of several global HSR development initiatives to understand the critical motivators for investment in HSR as a transportation system. Common among all HSR initiatives is the reduction in dependence on expensive fuels required for more conventional transportation modes, such as air travel and highway travel. In the US, for example, the consumption of jet fuel has been consistently 7 percent of total energy consumption of all transportation modes since 2005. In 2009, SBI Energy estimates that 1,875 trillion BTUs of jet fuel were consumed for US-based air travel, compared to 1,873 trillion BTUs in 2005. The greatest share of energy consumption is from motor fuels for passenger cars and motorcycles; 36 percent for 2009. Class 1 Rails (defined as operators with more than $250 million in revenue) consume the least amount of diesel fuel energy. The efficient manner in which railroads transport people and freight is a primary driver for HSR investment in nations dependent upon intercity transportation.

ARRA Energy Report Card: Two Years Later


Subscribe to: Posts (Atom)

Welcome to SEO Consultant Blog

Thank you for taking the time to visit my blog! Take a second to peak around and check out some of my previous posts. You will find here latest news related to SEO industry

Find me on Bloggers.com

Find me on Bloggers.com